Literature DB >> 33922404

High Resistance of Salmonella spp. and Shigella spp. in Blood and Stool Cultures from the Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal, 2015-2019.

Anup Bastola1, Prajjwal Pyakurel2, Rajan Bikram Rayamajhi3, Saugat Shrestha3, Pruthu Thekkur4,5, Basudev Pandey1, Parmananda Bhandari1, Anu Maharjan6, Jeffrey K Edwards7.   

Abstract

Antimicrobial resistance (AMR) is an increasing global concern, particularly in Southeast Asian countries like Nepal. The aim of this study was to determine the proportion of Salmonella spp. and Shigella spp. among culture-positive bacterial isolates in blood and stool samples from 2015 to 2019 and their AMR pattern. Routinely collected data were abstracted from medical records and laboratory electronic databases of the Sukraraj Tropical and Infectious Disease Hospital (STIDH), Kathmandu, Nepal. All culture-positive bacterial isolates from blood and stool samples were included in the study. Among 390 blood cultures positive for bacterial isolates, Salmonella spp. were isolated in 44%, with S. Typhi being the most frequent (34%). Antibiotic resistance was demonstrated among Salmonella spp. to ciprofloxacin (68%), ofloxacin (16%), amoxicillin (13%) and cotrimoxazole (5%). Of the 357 stool cultures positive for bacterial isolates, the proportion of Shigella spp. isolated was 31%. Antibiotic resistance among Shigella spp. was demonstrated to cotrimoxazole (59%), tetracycline (40%), amoxicillin (38%) and ciprofloxacin (25%). Salmonella spp. and Shigella spp. were the most predominant organisms among all the bacterial isolates in blood and stool cultures, respectively. Nalidixic acid was the antibiotic to which both Salmonella spp. and Shigella spp. were most resistant.

Entities:  

Keywords:  Nepal; Salmonella spp.; Shigella spp.; antimicrobial resistance; operational research

Year:  2021        PMID: 33922404     DOI: 10.3390/tropicalmed6020059

Source DB:  PubMed          Journal:  Trop Med Infect Dis        ISSN: 2414-6366


  18 in total

Review 1.  Mechanisms of resistance to quinolones.

Authors:  George A Jacoby
Journal:  Clin Infect Dis       Date:  2005-07-15       Impact factor: 9.079

Review 2.  Kathmandu, Nepal: still an enteric fever capital of the world.

Authors:  Abhilasha Karkey; Amit Aryjal; Buddha Basnyat; Stephen Baker
Journal:  J Infect Dev Ctries       Date:  2008-12-01       Impact factor: 0.968

3.  The Effect of the 2015 Earthquake on the Bacterial Community Compositions in Water in Nepal.

Authors:  Sital Uprety; Pei-Ying Hong; Nora Sadik; Bipin Dangol; Rameswor Adhikari; Antarpreet Jutla; Joanna L Shisler; Patrick Degnan; Thanh H Nguyen
Journal:  Front Microbiol       Date:  2017-12-06       Impact factor: 5.640

Review 4.  Antimicrobial Resistance in Nepal.

Authors:  Krishna Prasad Acharya; R Trevor Wilson
Journal:  Front Med (Lausanne)       Date:  2019-05-24

Review 5.  The STROBE guidelines.

Authors:  Sarah Cuschieri
Journal:  Saudi J Anaesth       Date:  2019-04

Review 6.  Antimicrobial resistance in human populations: challenges and opportunities.

Authors:  S Allcock; E H Young; M Holmes; D Gurdasani; G Dougan; M S Sandhu; L Solomon; M E Török
Journal:  Glob Health Epidemiol Genom       Date:  2017-05-10

7.  A current perspective on antimicrobial resistance in Southeast Asia.

Authors:  Raphaël M Zellweger; Juan Carrique-Mas; Direk Limmathurotsakul; Nicholas P J Day; Guy E Thwaites; Stephen Baker
Journal:  J Antimicrob Chemother       Date:  2017-11-01       Impact factor: 5.790

8.  Dominant serotype distribution and antimicrobial resistance profile of Shigella spp. in Xinjiang, China.

Authors:  Hongbo Liu; Binghua Zhu; Shaofu Qiu; Yidan Xia; Beibei Liang; Chaojie Yang; Nian Dong; Yongrui Li; Ying Xiang; Shan Wang; Jing Xie; Muti Mahe; Yansong Sun; Hongbin Song
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

9.  Tackling antimicrobial resistance in low-income and middle-income countries.

Authors:  Sunil Pokharel; Shristi Raut; Bipin Adhikari
Journal:  BMJ Glob Health       Date:  2019-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.